Your Article Summary
See Latest ArticlesPopulation pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
European Journal of Cancer, 06/15/09
Thomas F et al. - Study concludes that erlotinib treatment may present criteria justifying dose individualisation but further studies, including more patients, are necessary to define the modalities of this adaptation.
Methods- Study was undertaken to:
- Analyse the impact of several covariates on the pharmacokinetics of erlotinib and its main metabolite (OSI-420) and
- Determine pharmacokinetic/pharmacodynamic (PK/PD) relationships
- Plasma concns of erlotinib and OSI-420 of 42 pts were analysed to evaluate the impact of pts’ covariates on erlotinib PK
- Presence of SNP in ABCB1 (2677G > T/A and 3435C > T), ABCG2 (421C > A) and CYP3A5 (6986G > A) was investigated
- PK/PD relationships between plasma drug exposure (AUC) and early drug response or toxicity were also studied
- Covariates retained to predict erlotinib clearance were ALAT (alanine amino transferase), age and ABCG2 polymorphism
- A significant link between drug exposure and the grade of skin rash was observed
- However, early response to treatment was not correlated to the erlotinib AUC
Related Articles
Basaloid squamous cell carcinomas of the head and neck
Bulletin du Cancer, 10/19/09
Relevance Score: 94%
HER2 expression predicts improved survival in patients with cervical node–positive head and neck squamous cell carcinoma
Otolaryngology Head and Neck Surgery, 10/13/09
Relevance Score: 94%
Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model
BMC: Journal of Biomedical Science, 11/17/09
Relevance Score: 93%
Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas
European Journal of Surgical Oncology, 11/16/09
Relevance Score: 93%
Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009
The Lancet Oncology, 11/02/09
Relevance Score: 93%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie
Anti-Cancer Drugs, 12/09/09
Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy
Anti-Cancer Drugs, 12/09/09
Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy
Medicinal Research Reviews, 12/09/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
British Journal of Clinical Pharmacology, 12/09/09
Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers
Current Medical Research and Opinion, 12/08/09
Subcutaneous Sumatriptan Pharmacokinetics: Delimiting the Monoamine Oxidase Inhibitor Effect
Headache: The Journal of Head and Face Pain, 12/08/09